References
- Y. M. Mesfin, A. Cheng, J. Lawrie and J. Buttery, Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review, BMJ Global Health 4(4) (2019) e001065 (14 pages); https://doi.org/10.1136/bmjgh-2018-001065
- European Medicines Agency (EMA), Comirnaty: EPAR – Public Assessment Report, EMA/707383/2020, December 2020; https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf; last access date September 15, 2022
- European Medicines Agency (EMA), Spikevax (previously COVID-19 Vaccine Moderna): EPAR – Public Assessment Report, EMA/15689/2021, January 2021; https://www.ema.europa.eu/en/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf; last access date September 15, 2022
- European Medicines Agency (EMA), Vaxzevria (previously COVID-19 Vaccine AstraZeneca): EPAR – Public Assessment Report, EMA/94907/2021, February 2021; https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public--assessment-report_en.pdf; last access date September 15, 2022
- European Medicines Agency (EMA), COVID-19 Vaccine Janssen: EPAR – Public Assessment Report, EMA/158424/2021, March 2021; https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf; last access date September 15, 2022
- D. Mevorach, E. Anis, N. Cedar, M. Bromberg, E. J. Haas, E. Nadir, S. Olsha-Castell, D. Arad, T. Hasin, N. Levi, R. Asleh, O. Amir, K. Meir, D. Cohen, R. Dichtiar, D. Novick, Y. Hershkovitz, R. Dagan, I. Leitersdorf, R. Ben-Ami, I. Miskin, W. Saliba, K. Muhsen, Y. Levi, M. S. Green, L. Keinan-Boker and S. Alroy-Preis, Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel, N. Engl. J. Med. 385(23) (2021) 2140–2149; https://doi.org/10.1056/NEJMoa2109730
- Ø. Karlstad, P. Hovi, A. Husby, T. Härkänen, R. M. Selmer, N. Pihlström, J. V. Hansen, H. Nohynek, N. Gunnes, A. Sundström, J. Wohlfahrt, T. A. Nieminen, M. Grünewald, H. L. Gulseth, A. Hviid and R. Ljung, SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents, JAMA Cardiol. 7(6) (2022) 600–612; https://doi.org/10.1001/jamacardio.2022.0583
- A. Greinacher, T. Thiele, T. E. Warkentin, K. Weisser, P. A. Kyrle and S. Eichinger, Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination, N. Engl. J. Med. 384(22) (2021) 2092–2101; https://doi.org/10.1056/NEJMoa2104840
- European Medicines Agency (EMA), Guideline on Good Pharmacovigilance Practices (GVP): Module IX – Signal management, Current revision 1 version, EMA/827661/2011, October 2017; https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf; last access date January 20, 2023
- H. Azarpanah, M. Farhadloo, R. Vahidov and L. Pilote, Vaccine hesitancy: evidence from an adverse events following immunization database, and the role of cognitive biases, BMC Public Health 21(1) (2021) Article ID 1686 (13 pages); https://doi.org/10.1186/s12889-021-11745-1
- X. Kurz, F. Domergue, J. Slattery, A. Segec, A. Szmigiel and A. Hidalgo-Simon, Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance, Vaccine 29(26) (2011) 4378–4387; https://10.1016/j.vaccine.2011.04.005
- M. Sturkenboom, P. Bahri, A. Chiucchiuini, T. Grove Krause, S. Hahné, A. Khromava, M. Kokki, P. Kramarz, X. Kurz, H. J. Larson, S. de Lusignan, P. Mahy, L. Torcel-Pagnon, L. Titievsky, V. Bauchau, Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines?, Vaccine 38 Supplement 2 (2020) B1-B7; https://doi.org/10.1016/j.vaccine.2019.07.081
- European Medicines Agency (EMA), EudraVigilance, https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance; last access date September 16, 2022
- European Medicines Agency (EMA), Guideline on Good Pharmacovigilance Practices (GVP): Module VI – Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products, Current revision 2 version, EMA/873138/2011, July 2017; https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf; last access date September 16, 2022
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Medical Dictionary for Regulatory Activities (MedDRA), MedDRA® Data Retrieval and Presentation: Points to Consider ICH-Endorsed Guide for Meddra Users on Data Output, Release 3.22, March 2022; https://admin.meddra.org/sites/default/files/guidance/file/000715_datretptc_r3_22_mar2022.pdf; last access date September 16, 2022
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Medical Dictionary for Regulatory Activities (MedDRA), MedDRA Hierarchy, https://www.meddra.org/how-to-use/basics/hierarchy; last access on September 16, 2022
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Medical Dictionary for Regulatory Activities (MedDRA), Standardised MedDRA Queries, https://www.meddra.org/standardised-meddra-queries; last access on September 16, 2022
- European Medicines Agency (EMA), MedDRA Important medical event terms list, Current version 25.1, EMA/782876/2022, 26 September 2022; https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-system-overview; last access on February 15, 2023
- K. S. Kohl, J. Bonhoeffer, M. M. Braun, R. T. Chen, P. Duclos, H. Heijbel, U. Heininger, E. Loupi, and S. M. Marcy, The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization, in Advances in Patient Safety: From Research to Implementation, Vol. 2: Concepts and Methodology (Eds. K. Henriksen, J. B. Battles, E. S. Marks and D. I. Lewin), Agency for Healthcare Research and Quality, Rockville (MD, USA) 2005, pp. 87–102; https://www.ncbi.nlm.nih.gov/books/NBK20507/; last access on May 10, 2022
- The Brighton Collaboration, Brighton Collaboration Case Definitions; https://brightoncollaboration.us/category/pubs-tools/case-definitions/; last access on May 10, 2022
- J. Chapin-Bardales, J. Gee and T. Myers, Reactogenicity following receipt of mRNA-based COVID-19 vaccines, JAMA 325(21) (2021) 2201–2202; https://doi.org/10.1001/jama.2021.5374
- D. K. Shay, J. Gee, J. R. Su, T. R. Myers, P. Marquez, R. Liu, B. Zhang, C. Licata, T. A. Clark and T. T. Shimabukuro, Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine — United States, March–April 2021, Morb. Mortal. Wkly. Rep. 70(18) (2021) 680–684; https://www.cdc.gov/mmwr/volumes/70/wr/mm7018e2.htm
- M. Voysey, S. A. C. Clemens, S. A. Madhi, L. Y. Weckx, P. M. Folegatti, P. K. Aley, B. Angus, V. L. Baillie, S. L. Barnabas, Q. E. Bhorat, S. Bibi, C. Briner, P. Cicconi, A. M. Collins, R. Colin-Jones, C. L. Cutland, T. C. Darton, K. Dheda, C. J. A. Duncan, K. R. W. Emary, K. J. Ewer, L. Fairlie, S. N. Faust, S. Feng, D. M. Ferreira, A. Finn, A. L. Goodman, C. M. Green, C. A. Green, P. T. Heath, C. Hill, H. Hill, I. Hirsch, S. H. C. Hodgson, A. Izu, S. Jackson, D. Jenkin, C. C. D. Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A. M. Lawrie, A. Lelliott, V. Libri, P. J. Lillie, R. Mallory, A. V. A. Mendes, E. P. Milan, A. M. Minassian, A. McGregor, H. Morrison, Y. F. Mujadidi, A. Nana, P. J. O’Reilly, S. D. Padayachee, A. Pittella, E. Plested, K. M. Pollock, M. N. Ramasamy, S. Rhead, A. V. Schwarzbold, N. Singh, A. Smith, R. Song, M. D. Snape, E. Sprinz, R. K. Sutherland, R. Tarrant, E. C. Thomson, M. E. Török, M. Toshner, D. P. J. Turner, J. Vekemans, T. L. Villafana, M. E. E. Watson, C. J. Williams, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert, and A. J. Pollard (Oxford COVID vaccine trial group), Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet 397(10269) (2021) 99–111; https://doi.org/10.1016/S0140-6736(20)32661-1
- K. Ali, G. Berman, H. Zhou, W. Deng, V. Faughnan, M. Coronado-Voges, B. Ding, J. Dooley, B. Girard, W. Hillebrand, R. Pajon, J. M. Miller, B. Leav and R. McPhee, Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents, N. Engl. J. Med. 385(24) (2021) 2241–2251; https://doi.org/10.1056/NEJMoa2109522
- Y. June Choe, S. Yi, I. Hwang, J. Kim, Y. J. Park, E. Cho, M. Jo, H. Lee and E. Hwa Choi, Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents, Vaccine 40(5) (2022) 691–694; https://doi.org/10.1016/j.vaccine.2021.12.044
- G. Li, F. Cappuccini, N. G. Marchevsky, P. K. Aley, R. Aley, R. Anslow, S. Bibi, K. Cathie, E. Clutter-buck, S. N. Faust, S. Feng, P. T. Heath, S. Kerridge, A. Lelliott, Y. Mujadidi, K. F. Ng, S. Rhead, H. Roberts, H. Robinson, M. R. Roderick, N. Singh, D. Smith, M. D. Snape, R. Song, K. Tang, A. Yao, X. Liu, T. Lambe and A. J. Pollard (the COV006 study team), Safety and immunogenicity of the ChA-dOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial, Lancet 399(10342) (2022) 2212–2225; https://doi.org/10.1016/S0140-6736(22)00770-X (erratum in: Lancet 400(10345) (2022) 24)
- W. Fu, B. Sivajohan, E. McClymont, A. Albert, C. Elwood, G. Ogilvie and D. Money, Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants, Int. J. Gynaecol. Obstet. 156(3) (2022) 406–417; https://doi.org/10.1002/ijgo.14008
- N. Luxi, A. Giovanazzi, A. Capuano, S. Crisafulli, P. M. Cutroneo, M. P. Fantini, C. Ferrajolo, U. Moretti, E. Poluzzi, E. Raschi, C. Ravaldi, C. Reno, M. Tuccori, A. Vannacci, G. Zanoni and G. Trifirò and Ilmiovaccino COVID19 collaborating group, COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: Overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety, Drug Safety 44(12) (2021) 1247–1269; https://doi.org/10.1007/s40264-021-01131-6
- A. Ciapponi, A. Bardach, A. Mazzoni, T. Alconada, S. A. Anderson, F. J. Argento, J. Ballivian, K. Bok, D. Comandé, E. Erbelding, E. Goucher, B. Kampmann, R. Karron, F. M. Munoz, M. C. Palermo, E. P. K. Parker, F. Rodriguez Cairoli, V. Santa María, A. S. Stergachis, G. Voss, X. Xiong, N. Zamora, S. Zaraa, M. Berrueta and P. M. Buekens, Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review, Vaccine 39(40) (2021) 5891–5908; https://doi.org/10.1016/j.vaccine.2021.08.034
- W. A. Hauser, J. F. Annegers and L. T. Kurland, Prevalence of epilepsy in Rochester, Minnesota: 1940–1980, Epilepsia 32(4) (1991) 429–445; https://doi.org/10.1111/j.1528-1157.1991.tb04675.x
- E. Oka, Y. Ohtsuka, H. Yoshinaga, N. Murakami, K. Kobayashi and T. Ogino, Prevalence of childhood epilepsy and distribution of epileptic syndromes: a population-based survey in Okayama, Japan, 47(3) Epilepsia (2006) 626–630; https://doi.org/10.1111/j.1528-1167.2006.00477.x
- S. A. Russ, K. Larson and N. Halfon, A national profile of childhood epilepsy and seizure disorder, Pediatrics 129(2) (2012) 256–264; https://doi.org/10.1542/peds.2010-1371
- K. M. Aaberg, N. Gunnes, I. J. Bakken, C. Lund Søraas, A. Berntsen, P. Magnus, M. I. Lossius, C. Stoltenberg, R. Chin and P. Surén, Incidence and prevalence of childhood epilepsy: a nationwide cohort study, Pediatrics 139(5) (2017) e20163908 (9 pages); https://doi.org/10.1542/peds.2016-3908
- C. Dugas and V. H. Slane, Miscarriage, in StatPearls (updated 2022 Jun 27), StatPearls Publishing, Treasure Island (FL, USA), Internet 2022, Bookshelf ID: NBK532992 (4 pages).
- M. C. Magnus, A. J. Wilcox, N.-H. Morken, C. R. Weinberg and S. E. Håberg, Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study, BMJ 364(8192) (2019) Article ID I869 (8 pages); https://doi.org/10.1136/bmj.l869
- A. J. Wilcox, C. R. Weinberg, J. F. O’Connor, D. D. Baird, J. P. Schlatterer, R. E. Canfield, E. G. Armstrong and B. C. Nisula, Incidence of early loss of pregnancy, N. Engl. J. Med. 319(4) (1988) 189–194; https://doi.org/10.1056/NEJM198807283190401
- W. Fu, B. Sivajohan, E. McClymont, A. Albert, C. Elwood, G. Ogilvie and D. Money, Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants, Int. J. Gynaecol. Obstet. 156(3) (2022) 406–417; https://doi.org/10.1002/ijgo.14008
- L. H. Zauche, B. Wallace, A. N. Smoots, C. K. Olson, T. Oduyebo, S. Y. Kim, E. E. Peterson, J. Ju, J. Beauregard, A. J. Wilcox, C. E. Rose, D. M. Meaney-Delman and S. R. Ellington (for the CDC v-safe Covid-19 pregnancy registry team), Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion, N. Engl. J. Med. 385(16) (2021) 1533–1535; https://doi.org/10.1056/NEJMc2113891
- M. C. Magnus, H. K. Gjessing, H. N. Eide, A. J. Wilcox, D. B. Fell and S. E. Håberg, Covid-19 vacci-nation during pregnancy and first-trimester miscarriage, N. Engl. J. Med. 385(21) (2021) 2008–2010; https://doi.org/10.1056/NEJMc2114466
- D. A. Salmon and N. A. Halsey, Chapter 8 - How Vaccine Safety is Monitored, in The Vaccine Book (Eds. B. R. Bloom and P.-H. Lambert), 2nd ed., Elsevier-Academic Press, Amsterdam 2016, pp. 153–165; https://doi.org/10.1016/B978-0-12-802174-3.00008-4
- A. Buoninfante, A. Andeweg, A. T. Baker, M. Borad, N. Crawford, J. M. Dogné, D. Garcia-Azorin, A. Greinacher, R. Helfand, A. Hviid, S. Kochanek, M. López-Fauqued, I. Nazy, A. Padmanabhan, S. Pavord, D. Prieto-Alhambra, H. Tran, U. Wandel Liminga and M. Cavaleri, Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination, npj Vaccines 7 (2022) Article ID 141 (6 pages); https://doi.org/10.1038/s41541-022-00569-8
- G. Witberg, N. Barda, S. Hoss, I. Richter, M. Wiessman, Y. Aviv, T. Grinberg, O. Auster, N. Dagan, R. D. Balicer and R. Kornowski, Myocarditis after Covid-19 vaccination in a large health care organization, N. Engl. J. Med. 385(23) (2021) 2132–2139; https://doi.org/10.1056/NEJMoa2110737
- S. A. Buchan, C. Yon Seo, C. Johnson, S. Alley, J. C. Kwong, S. Nasreen, A. Calzavara, D. Lu, T. M. Harris, K. Yu and S. E. Wilson, Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada, JAMA Netw. Open 5(6) (2022) e2218505 (12 pages); https://doi.org/10.1001/jamanetworkopen.2022.18505
- European Medicines Agency (EMA), Signal Assessment Report on Myocarditis, Pericarditis with Tozinameran (COVID-19 mRNA vaccine (Nucleoside-Modified) – COMIRNATY), EPITT no: 19712, EMEA/H/C/005735/SDA/032.2, December 2021; https://www.ema.europa.eu/en/documents/pracrecom-mendation/signal-assessment-report-myocarditis-peri carditis-tozin ameran-covid-19-mrnavaccine_en.pdf; last access date September 19, 2022
- European Medicines Agency (EMA), COVID-19 Vaccine Safety Update: COVID-19 VACCINE JANSSEN, October 2021; https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-6-october-2021_en.pdf; last access date September 19, 2022
- European Medicines Agency (EMA), COVID-19 vaccine safety update: VAXZEVRIA, November 2021; https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-november-2021_en.pdf; last access date January 25, 2023
- L. Cari, M. Naghavi Alhosseini, P. Fiore, S. Pierno, S. Pacor, A. Bergamo, G. Sava and G. Nocentini, Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data, J. Autoimmun. 125 (2021) Article ID 102742 (17 pages); https://doi.org/10.1016/j.jaut.2021.102742
- N. Barda, N. Dagan, Y. Ben-Shlomo, E. Kepten, J. Waxman, R. Ohana, M. A. Hernán, M. Lipsitch, I. Kohane, D. Netzer, B. Y. Reis and R. D. Balicer, Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting, N. Engl. J. Med. 385(12) (2021) 1078–1090; https://doi.org/10.1056/nejmoa2110475
- M. J. Jabagi, J. Botton, M. Bertrand, A. Weill, P. Farrington, M. Zureik and R. Dray-Spira, Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older, JAMA 327(1) (2022) 80–82; https://doi.org/10.1001/jama.2021.21699
- J. Hippisley-Cox, M. Patone, X. W. Mei, D. Saatci, S. Dixon, K. Khunti, F. Zaccardi, P. Watkinson, M. Shankar-Hari, J. Doidge, D. A. Harrison, S. J. Griffin, A. Sheikh and C. A. C. Coupland, Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study, BMJ 374(8304) (2021) Article ID n1931 (11 pages); https://doi.org/10.1136/bmj.n1931
- C. R. Simpson, T. Shi, E. Vasileiou, S. V. Katikireddi, S. Kerr, E. Moore, C. McCowan, U. Agrawal, S. A. Shah, L. D. Ritchie, J. Murray, J. Pan, D. T. Bradley, S. J. Stock, R. Wood, A. Chuter, J. Beggs, H. R. Stagg, M. Joy, R. S. M. Tsang, S. de Lusignan, R. Hobbs, R. A. Lyons, F. Torabi, S. Bedston, M. O’Leary, A. Akbari, J. McMenamin, C. Robertson and A. Sheikh, First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland, Nat. Med. 27(7) (2021) 1290–1297; https://doi.org/10.1038/s41591-021-01408-4
- A. Pottegård, L. C. Lund, Ø. Karlstad, J. Dahl, M. Andersen, J. Hallas, Ø. Lidegaard, G. Tapia, H. Løvdal Gulseth, P. Lopez-Doriga Ruiz, S. Viksmoen Watle, A. Pretzmann Mikkelsen, L. Pedersen, H. Toft Sørensen, R. Wernich Thomsen and A. Hviid, Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population based cohort study, BMJ 373(8293) (2021) Article ID n114 (10 pages); https://doi.org/10.1136/bmj.n1114